热门资讯> 正文
Alkermes Initiates Phase 2 Trial of ALKS 2680 to Treat Narcolepsy Type 2
2024-08-22 21:01
09:01 AM EDT, 08/22/2024 (MT Newswires) -- Alkermes (ALKS) said Thursday it initiated a phase 2 Vibrance-2 study to evaluate the safety and efficacy of ALKS 2680, a once-daily potential treatment for narcolepsy, in comparison to placebo in adult patients with narcolepsy type 2.
Narcolepsy is a neurological disorder due to excessive daytime sleepiness.
The company said it plans to enroll roughly 80 participants with narcolepsy type 2 in the trial throughout the US, Australia, and Europe.
Alkermes is initiating the phase 2 trial based on the results from its phase 1 study, Chief Medical Officer Craig Hopkinson said.
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
